11 commercial payer policies list Q5109. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
11 policies from 5 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
| Policy | Effective | Status of Q5109 |
|---|---|---|
| Alzheimer's Disease: Experimental, Investigational, or Unproven Treatments | Feb 20, 2024 | Covered |
| Infliximab | Feb 15, 2024 | Covered |
| Vitiligo | Feb 16, 2024 | Covered |
| Policy | Effective | Status of Q5109 |
|---|---|---|
| Infliximab and Associated Biosimilars | Jan 1, 2026 | Covered |
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Policy | Effective | Status of Q5109 |
|---|
| Infliximab and Associated Biosimilars | Jan 1, 2026 | Covered |
|---|---|---|
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Policy | Effective | Status of Q5109 |
|---|---|---|
| Infliximab and Associated Biosimilars | Jan 1, 2026 | Covered |
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |
| Policy | Effective | Status of Q5109 |
|---|---|---|
| Infliximab and Associated Biosimilars | Jan 1, 2026 | Covered |
| Specialty Medication Administration Site of Care | Jan 1, 2026 | Covered |